Previous Article | Next Article 
Journal of Virology, February 1999, p. 1108-1117, Vol. 73, No. 2
0022-538X/99/$00.00+0
Envelope Formation Is Blocked by Mutation of a
Sequence Related to the HKD Phospholipid Metabolism Motif in the
Vaccinia Virus F13L Protein
Rachel L.
Roper and
Bernard
Moss*
Laboratory of Viral Diseases, National
Institute of Allergy and Infectious Diseases, Bethesda, Maryland
20892-0445
Received 22 July 1998/Accepted 20 October 1998
 |
ABSTRACT |
The outer envelope of the extracellular form of vaccinia virus is
derived from Golgi membranes that have been modified by the insertion
of specific viral proteins, of which the major component is the 37-kDa,
palmitylated, nonglycosylated product of the F13L gene. The F13L
protein contains a variant of the HKD (His-Lys-Asp) motif, which is
conserved in numerous enzymes of phospholipid metabolism. Vaccinia
virus mutants with a conservative substitution of either the K (K314R)
or the D (D319E) residue of the F13L protein formed only tiny plaques
similar to those produced by an F13L deletion mutant, were unable to
produce extracellular enveloped virions, and failed to mediate
low-pH-induced fusion of infected cells. Membrane-wrapped forms of
intracellular virus were rarely detected in electron microscopic images
of cells infected with either of the mutants. Western blotting and
pulse-chase experiments demonstrated that the D319E protein was less
stable than either the K314R or wild-type F13L protein. Most striking,
however, was the failure of either of the two mutated proteins to
concentrate in the Golgi compartment. Palmitylation, oleation, and
partitioning of the F13L protein in Triton X-114 detergent were
unaffected by the K314R substitution. These results indicated that the
F13L protein must retain the K314 and D319 for it to localize in the Golgi compartment and function in membrane envelopment of vaccinia virus.
 |
INTRODUCTION |
Vaccinia virus (VV), the most
intensively studied member of the Orthopoxvirus genus of the
family Poxviridae, was previously used as a smallpox vaccine
and is presently a vector in recombinant vaccine strategies to prevent
infectious diseases and to treat cancer (15, 30). The
characteristic features of orthopoxviruses are a double-stranded DNA
genome of approximately 200,000 bp, a cytoplasmic site of replication,
temporally regulated gene expression, and a complex process of
morphogenesis involving multiple viral membranes (29). VV
morphogenesis is the subject of this study.
VV forms several types of morphogenetically related particles. The
intracellular mature virions (IMV) have two closely apposed outer
membranes (45) and are infectious when released by cell lysis. To exit from an intact cell, the IMV undergo a second wrapping event and acquire two additional membrane layers from the trans-Golgi cisternae (20, 22, 41). The four membrane intracellular enveloped virions (IEV) then migrate to the cell periphery, where the
outermost viral membrane is lost during fusion with the plasma membrane
(22, 28). The externalized particles, with three remaining
membranes, may be released into the medium as extracellular enveloped
virions (EEV) or remain attached as cell-associated extracellular
enveloped virions (CEV) (5, 22, 28, 34, 41).
Since enveloped virus particles are primarily responsible for the
cell-to-cell spread of infection (1, 4, 7, 33, 47), the
wrapping of virus particles is of considerable interest. The following
six genes have been identified as encoding proteins that are
specifically incorporated into the outer envelope: A56R (35,
44), F13L (21), B5R (13, 24), A36R
(31), A34R (11), and A33R (38).
Information regarding the roles of the individual envelope proteins was
obtained by deletion of the cognate genes. Mutants with deleted A33R,
F13L, B5R, A36R, or A34R genes produced plaques that were much smaller
than those of wild-type (WT) virus, and those tested were attenuated in
vivo (4, 23, 27, 31, 39, 48). The block in virus spread may
be attributed to (i) a block in the wrapping of IMV to form IEV (e.g.,
the F13L and B5R genes) (4, 14, 48), (ii) a reduction in the
amount of EEV released (e.g., the A36R gene) (31), (iii) a
decrease in the infectivity of the EEV (A34R gene) (27), or
(iv) a lack of formation of specialized actin containing microvilli
that propel virus particles to the surface of infected cells (the A33R,
A34R, and A36R genes) (39, 40, 49, 50).
The WT F13L gene encodes a 37-kDa polypeptide that localizes to the
trans-Golgi membranes where the IMV are wrapped to form IEV
(41). The membrane association is mediated via palmitylation of one or both of two adjacent cysteine residues (18, 43). The F13L gene is highly conserved in poxviruses, and a homolog is
present in the distantly related molluscum contagiosum virus (3,
9), consistent with its important role in the virus life cycle.
Interestingly, the F13L protein contains two 16-amino-acid HKD motifs
(named for the most highly conserved residues), conserved in
phospholipases and phospholipid synthases (9, 26, 37, 46),
and possesses a broad-spectrum lipase activity (2). We
reported previously that virus mutants containing F13L protein with a
substitution of lysine to arginine at position 314 (K314R) or aspartic
acid to glutamic acid at position 319 (D319E) produced tiny plaques
similar to those of the F13L deletion (F13L
) mutant (46).
Here, we have described the effects of these two independent mutations
in the HKD motif of the VV F13L protein on the VV life cycle. The
small-plaque phenotype was due to a block in the wrapping of IMV to
form IEV. The data suggested that mutations of the HKD motif inhibited
morphogenesis due to changes in membrane localization of the F13L protein.
 |
MATERIALS AND METHODS |
Cells and antibodies.
VV stocks were prepared in HeLa cells
as described previously (12). BS-C-1 cells served for plaque
assays, immunoprecipitation, and Western blotting experiments, and
RK13 cells were used to propagate VV for CsCl purification.
Cells were grown in Eagle's minimal essential medium with 10% fetal
bovine serum (FBS), and infections were carried out with 2.5% FBS. For
titration of infectious VV and analysis of plaque size, monolayers were
fixed and stained with 0.1% crystal violet in 20% ethanol. Mouse
monoclonal antibody (MAb) 20 (B5R specific) and MAb 4 (A33R specific)
were previously described (32). The F13L peptide
RLVETLPENMDFRSDHLTTFEC (representing amino acids 14 to 35 of the F13L
protein) conjugated to keyhole limpet hemocyanin was injected into
rabbits to produce anti-F13L antibody.
Construction of viruses with F13L point mutations.
The
construction and purification of viruses with K314R or D319E point
mutations in the F13L gene and of a control virus with WT F13L sequence
(F13L+) have been previously described (46).
Immunoprecipitation and Western blotting.
Immunoprecipitates
and Western blots were made essentially as described previously
(38).
Triton X-114 partitioning.
Triton X-114 partitioning was
performed as previously described (38). After partitioning,
the detergent and aqueous phases were made equal in volume, detergent,
and salt concentration and analyzed by Western blotting or
immunoprecipitation and autoradiography.
Palmitate and oleate labeling of VV proteins.
Subconfluent
monolayers of BS-C-1 cells were infected with virus at a multiplicity
of 10 for 5 h. Medium was then replaced with Eagle's minimal
essential medium (no serum) with 200 µCi of [9,
10-3H(N)]palmitic acid in 10 µl of dimethyl sulfoxide or
100 µCi of [9, 10-3H(N)]oleaic acid in 20 µl of
ethanol per well. After 24 h, medium was removed and centrifuged
to pellet cells, which were then combined with cells scraped from
wells. The cells were lysed, and F13L proteins were immunoprecipitated,
solubilized in buffer containing 4% sodium dodecyl sulfate (SDS), 15 mM dithiothreitol, 0.05 M Tris base, 10% glycerol, and 0.1%
bromphenol blue, heated at 80°C for 3 min, analyzed by
SDS-polyacrylamide gel electrophoresis (PAGE), transferred to
Immobilon-P membrane (Millipore, Bedford, Mass.), and exposed to Kodak
Biomax MS film by using the Biomax TranScreen Low Energy intensifying
screen (Kodak, Rochester, N.Y.).
Syncytium formation.
Confluent BS-C-1 cell monolayers were
infected with virus at a multiplicity of 10 for 2 h, washed, and
incubated in medium for an additional 10 h as described previously
(4, 39). Cells were washed and treated with fusion buffer
[phosphate-buffered saline with 10 mM
2-(N-morpholino)ethanesulfonic acid and 10 mM N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid] at pH
5.5 or 7.4 for 2 min at 37°C. Afterwards, fusion buffer was replaced with medium, and the cells were incubated at 37°C and then observed by phase-contrast microscopy.
Virus purification.
Wrapped and unwrapped virus particles
were purified on the basis of their buoyant densities in CsCl gradients
as described previously (38). The refractive index of the
CsCl from samples was measured to verify correct collection of wrapped
and unwrapped virus particles.
Electron microscopy.
For transmission electron microscopy,
RK13 cells in 60-mm-diameter dishes were infected with VV
at a multiplicity of 10 for 24 h, fixed in 2% glutaraldehyde, and
embedded in Embed-812 (Electron Microscopy Sciences, Fort Washington,
Pa.) or fixed with increasing concentrations of paraformaldehyde and
prepared for immunoelectron microscopy as previously described
(49). Thawed cryosections were incubated with either rabbit
antibody to an F13L peptide or MAb 20, which recognizes the B5R protein
(32). The samples were washed, incubated with gold particles
conjugated to protein A (Department of Cell Biology, Utrecht University
School of Medicine, Utrecht, The Netherlands), and viewed with a
Philips CM 100 electron microscope.
Immunofluorescence microscopy.
Fluorescence microscopy was
performed as described previously (49). Infected HeLa cell
monolayers on coverslips were washed with phosphate-buffered saline,
fixed in 3% paraformaldehyde, and permeabilized with 0.05% saponin
(Calbiochem, San Diego, Calif.). Samples were stained with rabbit
anti-F13L antibody or MAb 4 to the VV A33R protein (32) as a
control, and then with rhodamine-conjugated swine anti-rabbit or
anti-mouse antibody (Dako Corporation, Carpinteria, Calif.). Samples
were viewed and images were collected using a Zeiss Axiophot, and
photographs were taken at identical exposure times.
 |
RESULTS |
Mutations of the F13L HKD motif cause a small-plaque
phenotype.
The VV F13L protein contains two previously identified
16-amino-acid HKD motifs at positions 118 to 133 and 312 to 327 (9, 26, 37). The second VV F13L HKD motif is more conserved
than the first and is the focus of this study. This sequence has an N
replacing the H in position 1 of the HKD motif. Therefore, because the
K at amino acid 314 and D at 319 are the most highly conserved residues, we decided to mutate these two amino acids (46) to determine if this motif might be important for the function of the F13L
protein in the VV life cycle. Viruses containing F13L point mutations,
K314R and D319E, made barely visible plaques after 48 h
(46). Here we compared the sizes of the plaques made by
F13L(K314R) and F13L(D319E) mutants to those of a control virus engineered for these studies, F13L+ (with a WT copy of the F13L gene
and the lacZ gene which is also present in the mutants), and
the F13L
mutant (Fig. 1). On day 2, mutant virus infection was observed macroscopically as tiny foci,
probably due to VV growth factor-induced cell proliferation
(8). By day 5, tiny plaques were visible. Significantly, the
plaques of the K314R and D319E mutants were similar to those of
F13L
, suggesting that the function of the F13L protein was
completely abrogated. In contrast, the plaques of F13L+ were quite
large on day 2 and had spread extensively by day 5. It is apparent that
the F13L HKD mutants do not form the diffuse elongated plaques, or
comets, that some viruses with mutated EEV proteins produce (even
though the parental WR [Western Reserve] virus does not form comets) and which are associated with increased release of wrapped virus particles into the medium (5, 27, 39). The results
demonstrated the importance of the F13L HKD motif for the function of
the F13L protein in cell-to-cell spread of VV.

View larger version (76K):
[in this window]
[in a new window]
|
FIG. 1.
Appearance of plaques formed by F13L mutants. BS-C-1
cell monolayers were infected with F13L+, F13L(K314R), F13L , or
F13L(D319E) virus. After 2 or 5 days, media were removed, and the
monolayers were fixed and stained with 0.1% crystal violet in 20%
ethanol. At day 2, each well contained more than 50 foci of infection
or plaques.
|
|
Expression of the mutated F13L proteins.
Western blot analysis
showed that the two HKD point mutants made readily detectable F13L
protein, although the D319E protein seemed reduced in amount. The
accumulation of F13L protein during infection was analyzed at 4, 8, and
24 h (Fig. 2). WT F13L protein was
barely detectable at 4 h, clearly visible at 8 h, and further increased at 24 h postinfection. The K314R protein showed a
similar pattern, with slightly less protein present at 24 h. The
D319E protein accumulated to 8 h, but then was reduced at 24 h, suggesting that this protein was less stable.

View larger version (44K):
[in this window]
[in a new window]
|
FIG. 2.
Synthesis and accumulation of F13L proteins. BS-C-1
cells were infected with F13L+, F13L(K314R), F13L , or F13L(D319E)
virus for 4, 8, and 24 h. Cell lysates were analyzed by SDS-PAGE,
transferred to a membrane, and probed with anti-F13L protein
antibodies. The molecular weights (thousands) of markers are shown to
the left. The arrow points to the F13L protein.
|
|
Stability of the mutated F13L proteins.
Pulse-chase
experiments were carried out to compare the stabilities of the mutated
and WT F13L proteins. Cells were infected with F13L+ or mutant viruses
for 8 h, metabolically labeled for 90 min with
[35S]methionine, and then harvested immediately or at 3-h
intervals after the return of the cells to normal media. F13L protein
was immunoprecipitated from the lysates and analyzed by SDS-PAGE and autoradiography. Although there were a number of background bands, a
unique 37-kDa protein was present in all lanes, except that of F13L
(Fig. 3). (The F13L
lane was also
missing a 120-kDa band which corresponds to the product of the
Escherichia coli lacZ gene, which was not present in this
recombinant virus [4]). The relative amounts of
[35S]methionine-labeled 37-kDa protein were determined
with a PhosphorImager. After the pulse, F13L(K314R) and F13L(D319E)
proteins were present at 90 and 88%, respectively, of the WT level.
After a 3-h chase incubation in unlabeled media, the amount of
F13L(K314R) protein remained near the WT level (120% of the WT level),
but the F13L(D319E) protein was reduced to 36% of the WT level. At
6 h, F13L(D319E) protein had degraded to 29% of the WT level, and
at 9 h, it had degraded to 16% of the WT level. In comparison,
F13L(K314R) protein was more stable, being reduced to 72% at 6 h
and 51% at 9 h of the F13L+ levels. The persistence of the K314R
protein, as determined by Western blotting and pulse-chase analysis,
suggested that the profound effect on plaque formation was not solely
due to protein instability. In the case of the D319E mutant, however,
protein instability may play a significant role.

View larger version (59K):
[in this window]
[in a new window]
|
FIG. 3.
Stability of F13L proteins. BS-C-1 cells were infected
with F13L+, F13L(K314R), F13L , or F13L(D319E) virus as indicated.
After 15 h of infection, the cells were incubated for 90 min with
[35S]methionine, and the cells were either lysed
immediately (pulse) or after an additional 3, 6, or 9 h of
incubation in normal culture media. The F13L protein was
immunoprecipitated, resolved by SDS-PAGE, and autoradiographed. The
molecular weights (thousands) of markers are shown in the center. The
arrows point to the F13L protein.
|
|
Triton X-114 phase partitioning of mutated F13L proteins.
While the F13L protein contains several hydrophobic regions, of which
one is predicted to be a transmembrane domain, the palmitylation state
also affects its hydrophobicity and membrane association (18, 20,
43). To compare the hydrophobic properties of the mutated and WT
F13L proteins, infected cells were metabolically labeled with
[35S]methionine for 24 h and then lysed in buffer
containing 2% Triton X-114. After extraction of proteins for 30 min,
insoluble matter was pelleted and analyzed by Western blotting. The
F13L+, K314R, and D319E pellets all contained detectable F13L protein
(Fig. 4A). The Triton X-114 soluble
material was then warmed to 37°C to allow separation of the detergent
and aqueous phases. F13L proteins were immunoprecipitated, analyzed by
SDS-PAGE, and autoradiographed (Fig. 4B). The WT F13L protein
partitioned completely to the detergent phase, as did the K314R F13L
protein, indicating their hydrophobicity and suggesting that the K314R
protein was also palmitylated (18, 43). In contrast to the
WT and K314R F13L proteins, the D319E F13L protein was not detected in
either the detergent phase or the aqueous phase (Fig. 4B), even after
extended autoradiography. This indicated that the D319E F13L protein
was not extracted by Triton X-114 and was entirely within the insoluble
pellet, as detected by Western blotting (Fig. 4A).

View larger version (60K):
[in this window]
[in a new window]
|
FIG. 4.
Triton X-114 (TX-114) partitioning of F13L proteins.
BS-C-1 cells were infected with F13L+, F13L(K314R), F13L , or
F13L(D319E) virus as indicated. After 6 h of infection, the cells
were incubated for 16 h with [35S]methionine and
extracted in 2% Triton X-114. Insoluble material was centrifuged and
analyzed by Western blotting (A). The Triton X-114 solution was warmed,
and the phases were separated. The F13L protein from each phase was
immunoprecipitated under identical salt and detergent conditions,
resolved by SDS-PAGE, and autoradiographed (B). The molecular weights
(thousands) (M) of markers are shown. The arrows point to the F13L
protein.
|
|
Since the D319E protein possessed altered solubility properties in
Triton X-114, we considered that the apparent instability
determined in
the previous section might be due in part to poor
solubility in
immunoprecipitation buffer containing 1% sodium
deoxycholate and 1%
Triton X-100. To evaluate this, cells were
infected for 24 h and
lysed in immunoprecipitation buffer. Western
blotting was performed
with the soluble and insoluble materials,
and the proteins were
quantitated (data not shown). In the case
of the F13L+ virus, 87% of
the F13L protein was present in the
supernatant. For the F13L(K314R)
and F13L(D319E) mutants, 78 and
53% of the F13L protein were soluble,
respectively. Therefore,
the reduced solubility of the mutated proteins
may have led to
a small underestimate of their stability as determined
by
immunoprecipitation.
Acylation of F13L proteins.
Since the mutant F13L proteins
were not functional, we were interested in determining if they were
posttranslationally modified as is WT F13L protein. The F13L protein
has been shown to be oleated and palmitylated (20, 32).
Since the acylation of a protein can determine its activation or
interaction with other proteins or membranes (18, 43), the
acylation status of the mutated F13L proteins was important to
determine. The WT F13L protein is palmitylated on cysteine residues 185 and 186 (18). Although this is 125 amino acids from the
location of the mutated HKD motif (Fig. 1), the effects of the point
mutations on protein folding or localization might affect processing.
Therefore, cells were infected and labeled with [9,
10-3H(N)]palmitic acid or [9,
10-3H(N)]oleaic acid, lysed with immunoprecipitation
buffer containing 0.1% SDS, immunoprecipitated, electrophoresed, and
autoradiographed. WT and K314R 37-kDa F13L proteins were both
palmitylated and oleated (Fig. 5).
However oleation or palmitylation of the F13L D319E protein was not
detected, even after quadrupling of the exposure time of the gel to
X-ray film. The immunoprecipitation buffer-insoluble material was also
analyzed, and distinct tritiated 37-kDa bands (data not shown) were
detected for F13L+ and the K314R mutant, but not for the D319E or
F13L
mutant, suggesting that the inability to detect acylated D319E
protein was not due to its altered solubility.

View larger version (68K):
[in this window]
[in a new window]
|
FIG. 5.
Palmitate and oleate labeling of VV proteins. BS-C-1
cells were infected with virus at a multiplicity of 10 for 5 h.
Medium was then replaced with medium containing 200 µCi of [9,
10-3H(N)]palmitic acid in 10 µl of dimethyl sulfoxide or
100 µCi of [9, 10-3H(N)]oleaic acid in 20 µl of
ethanol per well. After an additional 24 h, cells were lysed, and
F13L proteins were immunoprecipitated, analyzed by SDS-PAGE, and
exposed to film. The position of the 46-kDa marker is shown on the
left. The arrow points to the 37-kDa F13L protein.
|
|
Because the K314R protein partitioned into the Triton X-114 phase and
was acylated, it was expected to be membrane associated
(
18,
43). This association was confirmed by sucrose density
flotation
experiments (
51) (data not shown). The amount of labeled
D319E protein, however, was insufficient to determine membrane
association. Although the K314R mutation does not appear to alter
the
Triton X-114 partitioning, acylation, or membrane association
of the
F13L protein, the mutant virus nonetheless formed tiny
plaques.
Fusion of cells infected with F13L mutant virus.
Cells
infected with the F13L
do not undergo low-pH-induced fusion
(4). This process is believed to require wrapping and display of virus particles on the cell surface (4, 10, 17, 39,
48). Therefore, we evaluated the ability of the F13L point mutant
viruses to mediate acid fusion. Cells were infected for 12 h with
F13L+, F13L
, F13L(K314R), or F13L(D319E) virus, incubated for 2 min
in buffer at pH 5.5, returned to growth media, and, after 3 h,
examined microscopically. While infected cells maintained at neutral pH
did not fuse, brief acid treatment induced syncytium formation of F13L+
virus-infected cells. In contrast, none of the F13L mutants induced
polykaryon formation (Fig. 6), even
though the infected cells were observed for 12 h after the acid
treatment. As controls, we confirmed the inability of the A34R deletion
mutant to induce fusion and the ability of the A33R deletion mutant to do so (39, 49). These data suggested that the F13L HKD motif was required for cell fusion or that the HKD point mutants did not make
wrapped virus particles that were associated with the cell surface.

View larger version (144K):
[in this window]
[in a new window]
|
FIG. 6.
Induction of syncytia by F13L+ or F13L mutants. BS-C-1
cells were infected for 12 h, treated for 2 min with buffer at pH
5.5 or 7.4, and then returned to growth medium for 3 h and
examined by phase-contrast microscopy.
|
|
CsCl gradient centrifugation of virus particles.
Membrane-wrapped virions (IEV, CEV, and EEV) can be distinguished from
unwrapped IMV by their lower buoyant density in CsCl. To determine
whether the F13L mutations affected wrapping, cells were infected with
WT or mutant viruses, and the particles from the medium and cell
lysates were analyzed by CsCl centrifugation. While the production of
infectious unwrapped IMV by the HKD mutants was similar to that of
controls (WR and F13L+), the production of wrapped virus forms, both
cell-associated (IEV or CEV) and free (EEV), was reduced by 89 to 98%
(Table 1). These results were similar to
those found with F13L
(Table 1). The titer of virus infectivity was
determined before and after freeze-thawing and sonication (a procedure
used to increase infectivity of defective EEV by releasing IMV
[27]), with no significant difference in the result.
Consequently, the mutation of the K or the D in the HKD motif of the
F13L protein severely inhibited the ability of VV to form intracellular
wrapped virus particles or to release wrapped particles into the medium
(Table 1). This was consistent with the lack of comet formation in
infected-cell monolayers (Fig. 1) and the absence of low-pH-induced
cell fusion (Fig. 6).
Electron microscopic examination of cells infected with F13L mutant
virus.
Since the F13L
mutant virus is blocked in morphogenesis
at the stage of IMV wrapping to form IEV (4) and the F13L
point mutants form plaques the same size as those formed by the
deletion mutant, electron microscopy was used to analyze the effects of the mutations on morphogenesis. In cells infected with F13L+, numerous
wrapped IEV were visible (Fig. 7).
However, in the cells infected with the F13L
mutant or the F13L
point mutants, K314R and D319E, IMV were common, but IEV were rare or
absent, consistent with the result obtained by CsCl gradient
centrifugation of virus particles. Interestingly, rare IEV could be
seen in the D319E mutant virus, which makes the less stable F13L
protein, but they were almost completely absent in the K314R mutant
with the more stable F13L protein, indicating that the phenotypic
changes did not correlate with protein levels. These data indicated
that the F13L point mutants were blocked in membrane wrapping of IMV,
similar to the phenotype of the F13L
mutant.

View larger version (72K):
[in this window]
[in a new window]
|
FIG. 7.
Electron micrographs of Epon-embedded infected cells.
RK13 cells were infected with F13L+, F13L(K314R), or
F13L(D319E) virus. After 24 h, cells were fixed in glutaraldehyde
and embedded in Epon. In F13L+-infected cells, arrows point to examples
of wrapped IEV particles.
|
|
Localization of mutated F13L proteins by immunofluorescence.
The WT F13L protein has been shown to localize to the trans-Golgi
membranes which wrap IMV to form IEV (20, 41). Since efficient wrapping of the F13L HKD point mutant virus particles did not
occur, we investigated the intracellular localization of the mutant
F13L proteins. WT F13L protein showed the typical bright juxtanuclear
staining pattern characteristic of Golgi localization (Fig.
8) (20). Both the F13L(K314R)
and F13L(D319E) proteins showed levels of staining above that of
uninfected cells or the F13L
mutant, but the staining appeared to be
distributed throughout the cell rather than intensely localized in the
Golgi compartment. In the experiments described above, the cells were
also stained with antibody recognizing the surface- and Golgi-localized
A33R protein as a control for virus gene expression (38, 41)
(data not shown).

View larger version (104K):
[in this window]
[in a new window]
|
FIG. 8.
Immunofluorescence detection of F13L proteins. HeLa
cells were infected with F13L+, F13L(K314R), F13L , or F13L(D319E)
virus. At 16 h, the cells were fixed, permeabilized, and incubated
with antibodies to F13L protein and rhodamine-conjugated swine
anti-rabbit immunoglobulin.
|
|
Localization of mutated F13L proteins by immunogold electron
microscopy.
We investigated the localization of the F13L proteins
by comparing them with the VV B5R EEV protein, which also localizes to
the trans-Golgi network and wrapping membranes (41), by
using specific antibodies and two sizes of protein A-gold spheres. The 10- and 5-nm particles target the F13L and B5R proteins, respectively. We found that in VV strain WR-infected cells, membranes were heavily labeled for both proteins, with 92% of the F13L protein closely juxtaposed with B5R protein (Fig. 9 and
Table 2). Although wrapped IMV are rarely
seen in cells infected with the B5R and F13L deletion mutants, virus
protein-laden membranes may still be noted adjacent to IMV or localized
in vesicular structures. In both of the HKD point mutant virus-infected
cells, it was possible to see membranes heavily labeled for the B5R
protein, while the F13L protein was distributed throughout the cell,
rather than concentrated in particular areas. For this reason, it was
difficult to find electron microscope fields with concentrated labeling
of F13L protein. However, in the cells infected with the K314R mutant,
the F13L protein could occasionally be seen concentrated in discrete
membraneous structures, but these membranes were lacking B5R protein
(Fig. 9, lower right panel). Quantification indicated a high level of
K314R protein, of which only 24% was juxtaposed with the B5R protein
(Table 2). This value is similar to the background value of 23%
obtained in cells infected with F13L
(Table 2). For the D319E
mutant, there was less total staining of F13L protein, and only 19%
was adjacent to the B5R protein (Table 2). Thus the K314R and D319E F13L proteins did not localize with B5R protein above background levels. A B5R deletion mutant virus was also included as a control; background B5R staining was very low (Fig. 9), and only 1% juxtaposed with F13L protein. These data suggested that the block in IEV formation
was due to improper membrane localization of both the K314R and D319E
F13L proteins.

View larger version (136K):
[in this window]
[in a new window]
|
FIG. 9.
Immunogold labeling of viral membranes. RK13
cells were infected with WR, F13L(K314R), F13L , or F13L(D319E) virus
for 24 h, fixed in paraformaldehyde, cryosectioned, and double
labeled with antibodies specific to either the F13L (and 10-nm protein
A-gold spheres) or B5R (and 5-nm protein A-gold spheres) protein. Thick
and thin arrows point to representative 10- and 5-nm gold spheres,
respectively. Occasional 10-nm gold particles in the F13L are due to
background staining as quantified in Table 2.
|
|
 |
DISCUSSION |
We combined genetic, biochemical, and microscopic approaches to
investigate the role of the HKD motif of the F13L protein. Conservative
mutations of the K and D positions of the second VV F13L HKD motif
caused a small-plaque phenotype, indicating the functional importance
of this sequence. The F13L K314R and D319E phenotypes were as severe as
that of F13L
, indicating that the function of the F13L protein was
completely abrogated by these single-amino-acid mutations in the HKD
motif. The specificity of these mutations is demonstrated by several
other known amino acid changes not affecting plaque size (42, 16,
36).
Biochemical analyses showed that the properties of the K314R protein
were similar to those of WT F13L, while those of the D319E protein were
more severely altered. Thus the K314R mutant, which partitioned
normally in Triton X-114, was acylated and membrane bound. In contrast,
the D319E protein was less stable, was insoluble in Triton X-114, and
was less soluble than WT F13L protein in immunoprecipitation buffer.
Acylation of the D319E protein could not be detected, either because of
the small amount of the protein or because the mutated protein was
sequestered or degraded before it could undergo posttranslational modifications.
Small-plaque phenotypes have been associated with reductions in the
quantity (5, 31, 48) or infectivity (27) of
extracellular virus and with a defect in actin tail formation (39,
40, 49, 50). The F13L(K314R) and F13L(D319E) mutants mirror the
F13L
mutant in their formation of small plaques, lack of virus
released into the medium, and lack of comet formation. These data
uphold the correlation between EEV in the medium and the formation of elongated comet-shaped plaques under liquid medium (4-6, 27, 39). Both F13L HKD mutant viruses were blocked in morphogenesis at the stage of membrane wrapping of IMV to form IEV. Very few examples
of wrapped IEV were seen, and there was a log or more reduction in the
amount of EEV released into the media by the K314R and D319E mutants
compared to the F13L+ control viruses. The F13L point mutants did not
mediate acid-induced fusion of infected cells, consistent with previous
observations that formation of wrapping and display of virus on the
surface are necessary for acid-induced polykaryon formation (4,
10, 48).
Although the F13L(K314R) and F13L(D319E) proteins could be detected,
they did not localize properly to the Golgi compartment. These data
indicated that the HKD motif may be important for the proper sorting of
the F13L protein in intracellular membranes during VV infection. It has
previously been shown that F13L localization is dependent on other VV
protein(s) (25). In the case of the K314R mutant,
hydrophobicity, oleation, and palmitylation alone were insufficient to
direct the protein to its proper compartment in the membranes. Thus,
the K314 of the HKD motif was required for proper localization. It is
unknown whether the F13L HKD motif functions through an interaction
with another VV protein or directly with membranes. The data indicate
that there are three requirements for correct intracellular
localization of the F13L protein: (i) palmitylation (18,
43), (ii) another VV-encoded protein (25), and (iii)
amino acids in the HKD motif.
The HKD motif is conserved in phospholipases and phospholipid
synthases, leading to speculation that the VV F13L protein and the
process of envelopment require phospholipid biosynthesis or cleavage
(26, 37). Indeed, the VV F13L protein has now been characterized as a broad-specificity lipase, possessing triacylglycerol lipase and phospholipase A and C activities (2). The EEV is known to differ in phospholipid composition from the IMV
(19). However, the direct involvement of the 16 amino acids
of the VV F13L HKD motif in enzymatic activity seems unlikely for
several reasons. (i) Although this motif is characteristic of the
phospholipase D superfamily, phospholipase D activity of the VV F13L
protein has not been demonstrated (2, 46). (ii) The H is
believed to form part of a catalytic H, K, and D triad and is conserved in all phospholipase D enzymes, cardiolipin synthases, and phosphatidyl serine synthases, suggesting that it is essential for enzyme activity. (iii) None of the other enzymes in this family has an N replacing the H
at position 1 of the motif, as is found in the VV F13L HKD, and
mutation of the human phospholipase D HKD motif to NKD totally ablated
phospholipase D function (2, 46). (iv) Finally, F13L phospholipase A and C activities persisted after mutation of D319 (which causes a small-plaque phenotype) of the VV HKD motif
(2). Mutation of S327 of the VV F13L HKD motif (deemed
possibly to be important for phospholipase A or C activity) also did
not affect the reported phospholipase activity (2). One
interpretation is that the VV F13L HKD motif is involved in an
enzymatic activity not yet assayed, possibly even a phospholipid
synthesis activity. Another possibility is that the motif mediates a
nonenzymatic interaction of the F13L protein with phospholipids in
membranes needed for wrapping. This hypothesis is supported by the loss of proper membrane localization of the VV HKD mutants.
 |
ACKNOWLEDGMENTS |
We thank N. Cooper for cells, E. Wolffe for electron microscopy
and comments on the manuscript, A. Weisberg for electron microscopy and
help with preparation of figures, and D. Hruby and D. Grosenbach for
advice on palmitate labeling.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Laboratory of
Viral Diseases, National Institute of Allergy and Infectious Diseases, Building 4, Room 229, 4 Center Dr. MSC 0445, National Institutes of
Health, Bethesda, MD 20892-0445. Phone: (301) 496-9869. Fax: (301)
480-1147. E-mail: bmoss{at}nih.gov.
 |
REFERENCES |
| 1.
|
Appleyard, G.,
A. J. Hapel, and E. A. Boulter.
1971.
An antigenic difference between intracellular and extracellular rabbitpox virus.
J. Gen. Virol.
13:9-17[Abstract/Free Full Text].
|
| 2.
|
Baek, S.-H.,
J.-Y. Kwak,
S. H. Lee,
T. Lee,
S. H. Ryu,
D. J. Uhlinger, and J. D. Lambeth.
1997.
Lipase activities of p37, the major envelope protein of vaccinia virus.
J. Biol. Chem.
272:784-790.
|
| 3.
|
Blake, N. W.,
C. D. Porter, and L. C. Archard.
1991.
Characterization of a molluscum contagiosum virus homolog of the vaccinia virus p37K major envelope antigen.
J. Virol.
65:3583-3589[Abstract/Free Full Text].
|
| 4.
|
Blasco, R., and B. Moss.
1991.
Extracellular vaccinia virus formation and cell-to-cell virus transmission are prevented by deletion of the gene encoding the 37,000-dalton outer envelope protein.
J. Virol.
65:5910-5920[Abstract/Free Full Text].
|
| 5.
|
Blasco, R., and B. Moss.
1992.
Role of cell-associated enveloped vaccinia virus in cell-to-cell spread.
J. Virol.
66:4170-4179[Abstract/Free Full Text].
|
| 6.
|
Blasco, R.,
J. R. Sisler, and B. Moss.
1993.
Dissociation of progeny vaccinia virus from the cell membrane is regulated by a viral envelope glycoprotein: effect of a point mutation in the lectin homology domain of the A34R gene.
J. Virol.
67:3319-3325[Abstract/Free Full Text].
|
| 7.
|
Boulter, E. A., and G. Appleyard.
1973.
Differences between extracellular and intracellular forms of poxvirus and their implications.
Prog. Med. Virol.
16:86-108[Medline].
|
| 8.
|
Buller, R. M. L.,
S. Chakrabarti,
J. A. Cooper,
D. R. Twardzik, and B. Moss.
1988.
Deletion of the vaccinia virus growth factor gene reduces virus virulence.
J. Virol.
62:866-874[Abstract/Free Full Text].
|
| 9.
|
Cao, J. X.,
B. F. Koop, and C. Upton.
1997.
A human homolog of the vaccinia virus HindIII K4L gene is a member of the phospholipase D superfamily.
Virus Res.
48:11-18[Medline].
|
| 10.
|
Doms, R. W.,
R. Blumenthal, and B. Moss.
1990.
Fusion of intra- and extracellular forms of vaccinia virus with the cell membrane.
J. Virol.
64:4884-4892[Abstract/Free Full Text].
|
| 11.
|
Duncan, S. A., and G. L. Smith.
1992.
Identification and characterization of an extracellular envelope glycoprotein affecting vaccinia virus egress.
J. Virol.
66:1610-1621[Abstract/Free Full Text].
|
| 12.
|
Earl, P. L.,
N. Cooper, and B. Moss.
1991.
Preparation of cell cultures and vaccinia virus stocks, p. 16.16.1-16.16.7.
In
F. M. Ausubel, R. Brent, R. E. Kingston, D. D. Moore, J. G. Seidman, J. A. Smith, and K. Struhl (ed.), Current protocols in molecular biology, vol. 2. Wiley Interscience, New York, N.Y.
|
| 13.
|
Engelstad, M.,
S. T. Howard, and G. L. Smith.
1992.
A constitutively expressed vaccinia gene encodes a 42-kDa glycoprotein related to complement control factors that forms part of the extracellular virus envelope.
Virology
188:801-810[Medline].
|
| 14.
|
Engelstad, M., and G. L. Smith.
1993.
The vaccinia virus 42-kDa envelope protein is required for the envelopment and egress of extracellular virus and for virus virulence.
Virology
194:627-637[Medline].
|
| 15.
|
Fenner, F.,
D. A. Henderson,
I. Arita,
Z. Jezek, and I. D. Ladnyi.
1988.
Smallpox and its eradication, 1st ed.
World Health Organization, Geneva, Switzerland.
|
| 16.
|
Goebel, S. J.,
G. P. Johnson,
M. E. Perkus,
S. W. Davis,
J. P. Winslow, and E. Paoletti.
1990.
The complete DNA sequence of vaccinia virus.
Virology
179:247-266[Medline].
|
| 17.
|
Gong, S. C.,
C. F. Lai, and M. Esteban.
1990.
Vaccinia virus induces cell fusion at acid pH and this activity is mediated by the N-terminus of the 14-kDa virus envelope protein.
Virology
178:81-91[Medline].
|
| 18.
|
Grosenbach, D. W.,
D. O. Ulaero, and D. E. Hruby.
1997.
Palmitylation of the vaccinia virus 37-kDa major envelope antigen.
J. Biol. Chem.
272:1956-1964[Abstract/Free Full Text].
|
| 19.
|
Hiller, G.,
H. Eibl, and K. Weber.
1981.
Characterization of intracellular and extracellular vaccinia virus variants: N1-isonicotinoyl-N2-3-methyl-4-chlorobenzoylhydrazine interferes with cytoplasmic virus dissemination and release.
J. Virol.
39:903-913[Abstract/Free Full Text].
|
| 20.
|
Hiller, G., and K. Weber.
1985.
Golgi-derived membranes that contain an acylated viral polypeptide are used for vaccinia virus envelopment.
J. Virol.
55:651-659[Abstract/Free Full Text].
|
| 21.
|
Hirt, P.,
G. Hiller, and R. Wittek.
1986.
Localization and fine structure of a vaccinia virus gene encoding an envelope antigen.
J. Virol.
58:757-764[Abstract/Free Full Text].
|
| 22.
|
Ichihashi, Y.,
S. Matsumoto, and S. Dales.
1971.
Biogenesis of poxviruses: role of A-type inclusions and host cell membranes in virus dissemination.
Virology
46:507-532[Medline].
|
| 23.
| Isaacs, S., R. Blasco, and B. Moss. Unpublished
observations.
|
| 24.
|
Isaacs, S. N.,
E. J. Wolffe,
L. G. Payne, and B. Moss.
1992.
Characterization of a vaccinia virus-encoded 42-kilodalton class I membrane glycoprotein component of the extracellular virus envelope.
J. Virol.
66:7217-7224[Abstract/Free Full Text].
|
| 25.
|
Katz, E.,
E. J. Wolffe, and B. Moss.
1997.
The cytoplasmic and transmembrane domains of the vaccinia virus B5R protein target a chimeric human immunodeficiency virus type I glycoprotein to the outer envelope of nascent vaccinia virions.
J. Virol.
71:3178-3187[Abstract].
|
| 26.
|
Koonin, E. V.
1996.
A duplicated catalytic motif in a new superfamily of phosphohydrolases and phospholipid synthases that includes poxvirus envelope proteins.
Trends Biochem. Sci.
21:242-243[Medline].
|
| 27.
|
McIntosh, A. A. G., and G. L. Smith.
1996.
Vaccinia virus glycoprotein A34R is required for infectivity of extracellular enveloped virus.
J. Virol.
70:272-281[Abstract].
|
| 28.
|
Morgan, C.
1976.
Vaccinia virus reexamined: development and release.
Virology
73:43-58[Medline].
|
| 29.
|
Moss, B.
1996.
Poxviridae: the viruses and their replication, p. 2637-2671.
In
B. N. Fields, D. M. Knipe, and P. M. Howley (ed.), Fields virology, vol. 2. Lippincott-Raven Press, New York, N.Y.
|
| 30.
|
Moss, B.
1991.
Vaccinia virus: a tool for research and vaccine development.
Science
252:1662-1667[Abstract/Free Full Text].
|
| 31.
|
Parkinson, J. E., and G. L. Smith.
1994.
Vaccinia virus gene A36R encodes a M(r) 43-50 K protein on the surface of extracellular enveloped virus.
Virology
204:376-390[Medline].
|
| 32.
|
Payne, L. G.
1992.
Characterization of vaccinia virus glycoproteins by monoclonal antibody preparations.
Virology
187:251-260[Medline].
|
| 33.
|
Payne, L. G.
1980.
Significance of extracellular virus in the in vitro and in vivo dissemination of vaccinia virus.
J. Gen. Virol.
31:147-155.
|
| 34.
|
Payne, L. G., and K. Kristensson.
1979.
Mechanism of vaccinia virus release and its specific inhibition by N1-isonicatinoyl-N2-3-methyl-4-chlorobenzoylhydrazine.
J. Virol.
32:614-622[Abstract/Free Full Text].
|
| 35.
|
Payne, L. G., and E. Norrby.
1976.
Presence of haemagglutinin in the envelope of extracellular vaccinia virus particles.
J. Gen. Virol.
32:63-72[Abstract/Free Full Text].
|
| 36.
|
Pearson, W. R., and D. J. Lipman.
1988.
Improved tools for biological sequence comparison.
Proc. Natl. Acad. Sci. USA
85:2444-2448[Abstract/Free Full Text].
|
| 37.
|
Ponting, C. P., and I. D. Kerr.
1996.
A novel family of phospholipase D homologues that includes phospholipid synthases and putative endonucleases: identification of duplicated repeats and potential active site residues.
Protein Sci.
5:914-922[Medline].
|
| 38.
|
Roper, R. L.,
L. G. Payne, and B. Moss.
1996.
Extracellular vaccinia virus envelope glycoprotein encoded by the A33R gene.
J. Virol.
70:3753-3762[Abstract].
|
| 39.
|
Roper, R. L.,
E. J. Wolffe,
A. Weisberg, and B. Moss.
1998.
The envelope protein encoded by the A33R gene is required for formation of actin-containing microvilli and efficient cell-to-cell spread of vaccinia virus.
J. Virol.
72:4192-4204[Abstract/Free Full Text].
|
| 40.
|
Sanderson, C. M.,
F. Rischknecht,
M. Way,
M. Hollinshead, and G. L. Smith.
1998.
Roles of vaccinia virus EEV-specific proteins in intracellular actin tail formation and low pH-induced cell-cell fusion.
J. Gen. Virol.
79:1415-1425[Abstract].
|
| 41.
|
Schmelz, M.,
B. Sodeik,
M. Ericsson,
E. J. Wolffe,
H. Shida,
G. Hiller, and G. Griffiths.
1994.
Assembly of vaccinia virus: the second wrapping cisterna is derived from the trans Golgi network.
J. Virol.
68:130-147[Abstract/Free Full Text].
|
| 42.
|
Schmutz, C.,
L. G. Payne,
J. Gubser, and R. Wittek.
1991.
A mutation in the gene encoding the vaccinia virus 37,000-Mr protein confers resistance to an inhibitor of virus envelopment and release.
J. Virol.
65:3435-3442[Abstract/Free Full Text].
|
| 43.
|
Schmutz, C.,
L. Rindisbacher,
M. C. Galmiche, and R. Wittek.
1995.
Biochemical analysis of the major vaccinia virus envelope antigen.
Virology
213:19-27[Medline].
|
| 44.
|
Shida, H.
1986.
Nucleotide sequence of the vaccinia virus hemagglutinin gene.
Virology
150:451-462[Medline].
|
| 45.
|
Sodeik, B.,
R. W. Doms,
M. Ericcson,
G. Hiller,
C. E. Machamer,
W. van't Hof,
G. van Meer,
B. Moss, and G. Griffiths.
1993.
Assembly of vaccinia virus: role of the intermediate compartment between the endoplasmic reticulum and the Golgi stacks.
J. Cell Biol.
121:521-541[Abstract/Free Full Text].
|
| 46.
|
Sung, T.-C.,
R. L. Roper,
Y. Zhang,
S. A. Rudge,
R. Temel,
S. M. Hammond,
A. J. Morris,
B. Moss,
J. Engebrecht, and M. A. Frohman.
1997.
Mutagenesis of phospholipase D defines a superfamily including a trans-Golgi viral protein required for poxvirus pathogenicity.
EMBO J.
16:4519-4530[Medline].
|
| 47.
|
Turner, G. S., and E. J. Squires.
1971.
Inactivated smallpox vaccine: immunogenicity of inactivated intracellular and extracellular vaccinia virus.
J. Gen. Virol.
13:19-25[Abstract/Free Full Text].
|
| 48.
|
Wolffe, E. J.,
S. N. Isaacs, and B. Moss.
1993.
Deletion of the vaccinia virus B5R gene encoding a 42-kilodalton membrane glycoprotein inhibits extracellular virus envelope formation and dissemination.
J. Virol.
67:4732-4741[Abstract/Free Full Text].
|
| 49.
|
Wolffe, E. J.,
E. Katz,
A. Weisberg, and B. Moss.
1997.
The A34R glycoprotein gene is required for induction of specialized actin-containing microvilli and efficient cell-to-cell transmission of vaccinia virus.
J. Virol.
71:3904-3915[Abstract].
|
| 50.
|
Wolffe, E. J.,
A. S. Weisberg, and B. Moss.
1998.
Role for the vaccinia virus A36R outer envelope protein in the formation of virus-tipped actin-containing microvilli and cell-to-cell virus spread.
Virology
244:20-26[Medline].
|
| 51.
|
Zhang, J., and R. A. Lamb.
1996.
Characterization of the membrane association of the influenza virus matrix protein in living cells.
Virology
225:255-266[Medline].
|
Journal of Virology, February 1999, p. 1108-1117, Vol. 73, No. 2
0022-538X/99/$00.00+0
This article has been cited by other articles:
-
Smith, S. K., Olson, V. A., Karem, K. L., Jordan, R., Hruby, D. E., Damon, I. K.
(2009). In Vitro Efficacy of ST246 against Smallpox and Monkeypox. Antimicrob. Agents Chemother.
53: 1007-1012
[Abstract]
[Full Text]
-
Seo, J.-Y., Britt, W. J.
(2006). Sequence Requirements for Localization of Human Cytomegalovirus Tegument Protein pp28 to the Virus Assembly Compartment and for Assembly of Infectious Virus.. J. Virol.
80: 5611-5626
[Abstract]
[Full Text]
-
Roper, R. L.
(2006). Characterization of the Vaccinia Virus A35R Protein and Its Role in Virulence. J. Virol.
80: 306-313
[Abstract]
[Full Text]
-
Guo, Z. S., Naik, A., O'Malley, M. E., Popovic, P., Demarco, R., Hu, Y., Yin, X., Yang, S., Zeh, H. J., Moss, B., Lotze, M. T., Bartlett, D. L.
(2005). The Enhanced Tumor Selectivity of an Oncolytic Vaccinia Lacking the Host Range and Antiapoptosis Genes SPI-1 and SPI-2. Cancer Res.
65: 9991-9998
[Abstract]
[Full Text]
-
Yang, G., Pevear, D. C., Davies, M. H., Collett, M. S., Bailey, T., Rippen, S., Barone, L., Burns, C., Rhodes, G., Tohan, S., Huggins, J. W., Baker, R. O., Buller, R. L. M., Touchette, E., Waller, K., Schriewer, J., Neyts, J., DeClercq, E., Jones, K., Hruby, D., Jordan, R.
(2005). An Orally Bioavailable Antipoxvirus Compound (ST-246) Inhibits Extracellular Virus Formation and Protects Mice from Lethal Orthopoxvirus Challenge. J. Virol.
79: 13139-13149
[Abstract]
[Full Text]
-
Husain, M., Moss, B.
(2003). Intracellular Trafficking of a Palmitoylated Membrane-Associated Protein Component of Enveloped Vaccinia Virus. J. Virol.
77: 9008-9019
[Abstract]
[Full Text]
-
Upton, C., Slack, S., Hunter, A. L., Ehlers, A., Roper, R. L.
(2003). Poxvirus Orthologous Clusters: toward Defining the Minimum Essential Poxvirus Genome. J. Virol.
77: 7590-7600
[Abstract]
[Full Text]
-
Husain, M., Moss, B.
(2002). Similarities in the Induction of Post-Golgi Vesicles by the Vaccinia Virus F13L Protein and Phospholipase D. J. Virol.
76: 7777-7789
[Abstract]
[Full Text]
-
McCart, J. A., Ward, J. M., Lee, J., Hu, Y., Alexander, H. R., Libutti, S. K., Moss, B., Bartlett, D. L.
(2001). Systemic Cancer Therapy with a Tumor-selective Vaccinia Virus Mutant Lacking Thymidine Kinase and Vaccinia Growth Factor Genes. Cancer Res.
61: 8751-8757
[Abstract]
[Full Text]
-
Husain, M., Moss, B.
(2001). Vaccinia Virus F13L Protein with a Conserved Phospholipase Catalytic Motif Induces Colocalization of the B5R Envelope Glycoprotein in Post-Golgi Vesicles. J. Virol.
75: 7528-7542
[Abstract]
[Full Text]